Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published molecular biology and gerontology research. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, supplement regimen, or any health-related decision.

In the 1960s, Leonard Hayflick and Paul Moorhead made a counterintuitive observation in cultured human fibroblasts: the cells didn’t divide indefinitely. After a finite number of divisions — around 50 for most normal cell types — they stopped dividing entirely but remained metabolically active. This “Hayflick limit” was initially controversial and then foundational. What Hayflick observed was cellular senescence, and decades of subsequent work have made it one of the more credible mechanistic candidates for why biological aging accelerates in midlife and beyond.

The interest isn’t academic. Senescent cells accumulate in aging tissues, and their secretory behavior — not the arrested division itself, but what the cells release after arrest — is now a central topic in aging research. Japan has contributed substantively to this field through research on the Klotho protein’s intersection with senescence pathways, and through cohort work at institutions such as the National Center for Geriatrics and Gerontology (Obu, Aichi) that has examined inflammatory aging patterns in Japanese populations.

TL;DR

• Cellular senescence is a permanent cell cycle arrest mediated primarily by the p16^INK4a and p21^CIP1 cyclin-dependent kinase inhibitor pathways
• The senescence-associated secretory phenotype (SASP) — a sustained release of pro-inflammatory cytokines, matrix metalloproteinases, and growth factors from senescent cells — is associated with the chronic low-grade inflammation called inflammaging
• Senescent cell burden increases with age in human tissues; elevated p16^INK4a expression is among the most reproducible molecular markers of biological aging
• Japanese research groups have contributed to understanding the intersection of Klotho protein expression and senescence signaling, and to population-level evidence on inflammaging in Japanese aging cohorts
• Senolytics — compounds that selectively remove senescent cells — have moved from mouse models to Phase II human trials; dasatinib + quercetin and navitoclax are the most clinically studied candidates
• Calibration: animal model evidence for senolytics is extensive and robust; human Phase II trials are ongoing with some encouraging intermediate endpoints; no randomized controlled trial has established senolytic treatment as extending human lifespan or healthspan in a general population

How cells become senescent: p16, p21, and the arrest machinery

Senescence is not a single uniform state — it is a cell fate triggered by several distinct stressors, with shared downstream effectors. The two most studied triggers are replicative senescence (telomere shortening through repeated cell division) and stress-induced premature senescence, which encompasses oxidative damage, oncogene activation, DNA double-strand breaks, and radiation exposure.

Both converge on the cell cycle arrest machinery through two primary pathways. The p16^INK4a — Rb pathway activates when p16^INK4a, encoded by the CDKN2A locus on chromosome 9p21, accumulates in response to chronic stress signals. p16^INK4a inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which normally phosphorylate and inactivate the retinoblastoma protein (Rb). When Rb remains unphosphorylated, it sequesters E2F transcription factors needed for S-phase entry, blocking cell cycle progression. The arrest becomes self-reinforcing: p16^INK4a accumulation is both a cause and a consequence of chromatin restructuring in the senescent cell.

The p21^CIP1 — p53 pathway is triggered more acutely by DNA damage. ATM and ATR kinases detect double-strand breaks and single-stranded DNA, respectively, and activate p53, which transcriptionally induces p21^CIP1. p21^CIP1 inhibits a broader spectrum of CDKs than p16^INK4a, producing arrest at both the G1/S and G2/M checkpoints. p21 activation is often the initial brake; in cells that go on to establish stable senescence, p16 accumulation typically reinforces and locks in the arrest over subsequent days and weeks.

What makes senescent cells biologically costly to surrounding tissue is not the arrested cell itself but what it secretes.

SASP and inflammaging

The senescence-associated secretory phenotype was named and characterized in detail by Judith Campisi’s laboratory at the Buck Institute for Research on Aging through the late 2000s. Campisi’s group showed that senescent human fibroblasts — whether induced by replicative exhaustion, radiation, or oncogene activation — developed a sustained secretory profile characterized by elevated interleukin-6 (IL-6), IL-8, monocyte chemoattractant protein-1 (MCP-1), and a range of matrix metalloproteinases including MMP-3, MMP-1, and MMP-10. Growth factors including VEGF and HGF are also components of SASP.

The breadth of this profile matters. IL-6 is among the most consistently elevated inflammatory cytokines in older adults across cross-sectional population data, including in Japanese aging cohort studies. MMP secretion degrades the extracellular matrix surrounding cells, potentially disrupting tissue architecture and facilitating changes in neighboring cell behavior. The paracrine effects of SASP — where one senescent cell’s secretions alter behavior in adjacent non-senescent cells — create a spreading pro-inflammatory microenvironment that can induce secondary senescence through sustained signaling.

Claudio Franceschi at the University of Bologna coined the term “inflammaging” around 2000 to describe the chronic low-grade pro-inflammatory state associated with aging — a shift toward elevated circulating inflammatory markers without acute infection or injury. SASP provides a mechanistic candidate for how senescent cell accumulation might drive or amplify inflammaging. The causal direction — whether senescent cell accumulation drives inflammaging, or whether chronic low-grade inflammation accelerates senescence — is not fully resolved from population data. Both directions are biologically plausible, and most researchers view the relationship as bidirectional and self-reinforcing.

Japan’s research contributions: Klotho, p21, and geriatric cohort evidence

The connection between Klotho — the aging-regulatory protein identified at the University of Tokyo in 1997 and covered in detail in the Klotho protein and aging article — and cellular senescence involves both the p21 pathway and SASP signaling. Soluble Klotho, the circulating form shed from kidney tubular cells, has been shown in cell culture and rodent studies to suppress Wnt signaling and reduce TGF-β activity, both of which are implicated in SASP-driven tissue fibrosis when chronically activated. In klotho-deficient mice, elevated inflammatory markers consistent with SASP co-occur with the accelerated tissue deterioration phenotype — suggesting that Klotho expression may modulate the senescence burden in aging tissues.

Research at Osaka University has examined p21-mediated cellular senescence in cardiovascular and metabolic disease contexts, including how senescent vascular smooth muscle cells and endothelial cells are associated with arterial stiffness progression — a finding relevant to the cardiovascular-longevity intersection documented in Japanese aging cohort data. Research at Nagoya University has contributed to understanding how Klotho expression affects senescence signaling in renal epithelial cells, providing molecular context for the observation that Klotho decline in aging kidneys correlates with accumulating senescent cell markers. These are specific but representative examples of a larger Japanese research contribution to the senescence-aging field.

The National Center for Geriatrics and Gerontology in Obu, Aichi Prefecture — which runs the National Institute for Longevity Sciences – Longitudinal Study of Aging (NILS-LSA) and the Obu Study on Health Promotion for the Elderly (OSHPE) — has contributed population-level evidence on inflammatory marker trajectories in older Japanese adults. Elevated IL-6 and elevated high-sensitivity CRP in these cohorts are associated with functional decline trajectories in longitudinal follow-up, consistent with the SASP-inflammaging framework applied to one of the world’s most aged societies. This is observational association data; the mechanisms through which elevated inflammatory markers are linked to functional outcomes remain active research.

The autophagy connection is relevant here. Impaired autophagic flux — the molecular maintenance process whose genetic machinery Yoshinori Ohsumi characterized and for which he received the 2016 Nobel Prize in Physiology or Medicine, covered in the Ohsumi Nobel and autophagy article — is associated with both aging cells and accumulating senescent cell burden. When damaged proteins and organelles accumulate because autophagy flux has declined, cellular stress signals increase, driving p21-mediated senescence responses in cells that might otherwise maintain normal cycling function. This makes senescence and autophagy dysfunction two reinforcing features of the aging cellular environment, with each likely compounding the other.

Senolytic trials: from INK-ATTAC mice to Phase II

The senolytic concept — that selectively removing senescent cells could improve biological outcomes in aging organisms — was first convincingly demonstrated in genetically engineered mice by Baker, Kirkland, and colleagues in a landmark 2011 Nature paper. The INK-ATTAC transgenic model allowed conditional elimination of p16^INK4a-positive cells; clearing these cells in middle-aged mice was associated with reduced burden of age-associated physical decline across multiple tissue systems, including skeletal muscle, fat, and kidney.

The translation question then became whether pharmacological approaches could replicate selective senescent cell removal without the genetic engineering. The dasatinib + quercetin (D+Q) combination emerged as a primary candidate following a 2015 Aging Cell study by Zhu et al. (Kirkland laboratory, Mayo Clinic) that identified dasatinib — an FDA-approved kinase inhibitor used in chronic myeloid leukemia — and quercetin — a dietary flavonoid found in onions, capers, and green tea — as independently acting senolytics that worked in a complementary fashion. The mechanism differs between the two: dasatinib primarily affects senescent fat progenitor cells through anti-apoptotic survival pathway inhibition; quercetin targets a broader range of senescent cell types through related but distinct survival signaling.

Phase II human trials on D+Q have been conducted in several disease contexts:

Diabetic kidney disease: A Phase I/II open-label pilot published in EBioMedicine in 2019 enrolled nine patients with diabetic kidney disease and administered intermittent D+Q dosing over three weeks. The study found reductions in skin and fat biopsy senescent cell markers and decreases in plasma SASP-related proteins following the treatment course. The sample size limits conclusions; this study is reported as a target engagement and safety assessment rather than an outcomes trial.

Idiopathic pulmonary fibrosis (IPF): A Phase II randomized, double-blind, placebo-controlled trial of D+Q in patients with IPF examined physical function endpoints. Published findings showed improvements in six-minute walk distance and related functional tests in the D+Q arm relative to placebo over a 20-week study period. IPF involves substantial fibroblast senescence and SASP-driven fibrosis, making it a well-chosen mechanistic test case. These results are encouraging intermediate data; IPF-specific outcomes do not directly generalize to aging broadly.

Frailty in older adults: Multiple pilots have examined D+Q in older adults with physical frailty. Groups including LeBrasseur’s laboratory at Mayo Clinic have published data showing reduced plasma SASP markers — including IL-6 and MMP-3 — following intermittent D+Q cycles in frail older adults. Effects on physical performance measures have varied across small trials, and larger powered trials are ongoing.

Navitoclax (ABT-263): A BCL-2 and BCL-xL inhibitor originally developed as a cancer therapeutic, navitoclax reduces senescent cell burden in aging mice through blocking the anti-apoptotic survival machinery that senescent cells upregulate relative to non-senescent cells. Animal data showing reduced age-associated pathology and lifespan extension in aged rodents is robust across several laboratories. Human Phase I/II trials exist in the context of oncology, where the dose-limiting toxicity — thrombocytopenia from platelet depletion due to BCL-xL inhibition in platelets — has been documented. Modified navitoclax derivatives and platelet-sparing BCL-family-targeting compounds, including UBX1325 (Unity Biotechnology), have entered trials in ophthalmology for age-related macular degeneration and diabetic macular edema, where local intraocular delivery reduces systemic toxicity concerns.

Where this research stands

The animal model evidence for senolytics is among the most extensive and reproducible in gerontology research — the INK-ATTAC genetic model and pharmacological D+Q results have been replicated by multiple independent laboratories across different aging mouse cohorts. The challenge is that animal model evidence has historically preceded positive human trials by years, and not all animal longevity findings translate to humans.

Human Phase II trial data on D+Q shows meaningful intermediate endpoint findings in disease-specific contexts. These establish that the approach is biologically active in humans and engages with senescent cell markers as measured in tissue biopsies and plasma. What they do not yet establish: whether reducing senescent cell burden extends healthspan or lifespan in non-diseased or generally aging populations. That requires trials of longer duration, larger sample sizes, and clinical outcome endpoints rather than biomarker endpoints — trials that are in design or early enrollment as of mid-2026.

Quercetin’s availability as a dietary supplement makes it widely accessible, and its senolytic mechanism has been documented in the published D+Q protocols. The clinical evidence, however, involves quercetin at specific doses (1,000 mg/day) administered in combination with dasatinib — a prescription oncology drug that is not a lay consumer option. Extrapolating the D+Q senolytic findings to self-directed quercetin supplementation alone involves a meaningful gap in the evidence. Quercetin as a standalone supplement at commonly available doses (250–1,000 mg/day) has a documented safety profile in human studies; its senolytic contribution in isolation, without dasatinib as the pairing agent, has not been established in published human trials. Those following this research area can find quercetin supplements on Amazon.

The NAD+ metabolism and sirtuin signaling overlap is worth noting here. SIRT1 activation through NAD+ raising — the pathway covered in detail in the sirtuins and NAD+ article — is proposed to suppress NF-κB-driven SASP secretion from senescent cells, potentially reducing the inflammatory burden without requiring their physical elimination. The mechanisms are complementary rather than competing; some researchers have proposed NAD+ precursor and senolytic co-administration as a rational combination approach, though human trial data for that combination has not been published. NMN and quercetin are both available in the supplement market for those tracking this research space — combined longevity supplement stacks are available on Amazon.

The centenarian genetics angle provides relevant context. Centenarians in Japanese cohorts show lower inflammatory marker profiles in cross-sectional data relative to younger old adults, which is consistent with the inflammaging hypothesis — covered in the centenarian genome article. Whether long-lived individuals accumulated fewer senescent cells across their lifespan, cleared them more efficiently, or have a fundamentally different SASP response profile is not separable from currently available data. The survival selection bias in centenarian cohorts makes this a particularly difficult mechanistic question.

For those interested in following the science as trials develop, annotated books on aging biology and the senescence research landscape are available on Amazon. If you are currently managing a chronic disease with potential senescence involvement — kidney disease, pulmonary fibrosis, Type 2 diabetes — discussing the senolytic trial landscape with a physician familiar with this research is the appropriate next step. Self-administration of dasatinib outside a clinical context is not appropriate; it is a prescription oncology drug with documented toxicity profiles that require medical supervision. Quercetin as a standalone supplement does not carry that restriction, but the clinical senolytic evidence that has attracted research attention involves dasatinib as the essential paired agent.

---

Research cluster: Klotho Protein and Aging: What the 1997 Japanese Discovery Actually Shows | Ohsumi’s Nobel and the Fasting Question: What the Autophagy Research Actually Shows | Sirtuins, NAD+, and Caloric Restriction: What the Molecular Pathway Research Actually Shows | Longevity Genes vs. Lifestyle: Epigenetic Clocks and Japanese Centenarian Genetics